Anna Richo

Insider Reports History

Reporting-owner location: Chicago, IL
Latest reporting-owner signature: Robert Maynes for Anna Richo
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Anna Richo

Form 4 holding Director

ILLUMINA, INC.

Security class: Common Stock
Shares / value: 8,527
Estimated value: $1,051,038
Report date: 21 May 2026
Price: $123.26
Ownership: Direct

Form 4 holding Director

EXELON CORP

Security class: Common stock- deferred stock units
Shares / value: 11,337
Estimated value: $455,019
Report date: 31 Mar 2026
Price: $43.87
Ownership: By Exelon Corp. Directors Deferred Stock Unit Plan

Form 4 holding Director

EXELON CORP

Security class: Deferred phantom share equivalents
Shares / value: 7,930
Estimated value: $385,318
Report date: 28 Apr 2026
Price: $48.59
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,930

Form 4 holding Director

EXELON CORP

Security class: 2026 Directors Restricted Stock Units
Shares / value: 3,720
Estimated value
Report date: 28 Apr 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

Adamas Pharmaceuticals Inc

Security class: Common Stock
Shares / value: 0
Estimated value
Report date: 24 Nov 2021
Price: $5.16
Ownership: Direct

Form 4 holding Director

Adamas Pharmaceuticals Inc

Security class: Stock Option (Right to Buy)
Shares / value: 0
Estimated value
Report date: 24 Nov 2021
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Anna Richo

4 ILMN

ILLUMINA, INC.

Report period: 21 May 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 22 May 2026, 17:12
Role: Director
Next action: Open filing details

4 EXC

EXELON CORP

Report period: 28 Apr 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 29 Apr 2026, 16:06
Role: Director
Next action: Open filing details

4 EXC

EXELON CORP

Report period: 31 Mar 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 01 Apr 2026, 15:28
Role: Director
Next action: Open filing details

4 EXC

EXELON CORP

Report period: 31 Dec 2025
Transactions: 2
Transaction value: +$72,492
Accepted by SEC: 02 Jan 2026, 15:07
Role: Director
Next action: Open filing details

4 EXC

EXELON CORP

Report period: 30 Sep 2025
Transactions: 2
Transaction value: +$72,495
Accepted by SEC: 01 Oct 2025, 20:46
Role: Director
Next action: Open filing details

4 EXC

EXELON CORP

Report period: 30 Jun 2025
Transactions: 2
Transaction value: +$72,479
Accepted by SEC: 02 Jul 2025, 09:39
Role: Director
Next action: Open filing details

4 ILMN

ILLUMINA, INC.

Report period: 21 May 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 23 May 2025, 17:05
Role: Director
Next action: Open filing details

4 EXC

EXELON CORP

Report period: 31 Mar 2025
Transactions: 2
Transaction value: +$72,472
Accepted by SEC: 02 Apr 2025, 14:26
Role: Director
Next action: Open filing details

4 EXC

EXELON CORP

Report period: 31 Dec 2024
Transactions: 2
Transaction value: +$72,499
Accepted by SEC: 03 Jan 2025, 10:38
Role: Director
Next action: Open filing details

4 EXC

EXELON CORP

Report period: 30 Sep 2024
Transactions: 2
Transaction value: +$72,500
Accepted by SEC: 02 Oct 2024, 13:29
Role: Director
Next action: Open filing details

4 EXC

EXELON CORP

Report period: 30 Jun 2024
Transactions: 2
Transaction value: +$72,515
Accepted by SEC: 02 Jul 2024, 16:02
Role: Director
Next action: Open filing details

4 ILMN

ILLUMINA, INC.

Report period: 16 May 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 22 May 2024, 17:22
Role: Director
Next action: Open filing details

3 ILMN

ILLUMINA, INC.

Report period: 16 May 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 22 May 2024, 17:12
Role: Director
Next action: Open filing details

4 EXC

EXELON CORP

Report period: 31 Mar 2024
Transactions: 2
Transaction value: +$72,480
Accepted by SEC: 02 Apr 2024, 14:07
Role: Director
Next action: Open filing details

4 EXC

EXELON CORP

Report period: 31 Dec 2023
Transactions: 2
Transaction value: +$72,482
Accepted by SEC: 02 Jan 2024, 20:50
Role: Director
Next action: Open filing details

4 EXC

EXELON CORP

Report period: 30 Sep 2023
Transactions: 2
Transaction value: +$47,720
Accepted by SEC: 02 Oct 2023, 18:36
Role: Director
Next action: Open filing details

3 EXC

EXELON CORP

Report period: 01 Aug 2023
Transactions: 0
Transaction value: $0
Accepted by SEC: 02 Aug 2023, 15:10
Role: Director
Next action: Open filing details

4

Adamas Pharmaceuticals Inc

Report period: 24 Nov 2021
Transactions: 3
Transaction value: $0
Accepted by SEC: 24 Nov 2021, 15:08
Role: Director
Next action: Open filing details

4

Adamas Pharmaceuticals Inc

Report period: 02 Jun 2021
Transactions: 2
Transaction value: $0
Accepted by SEC: 04 Jun 2021, 16:17
Role: Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .